Table S2 from APC/C-CDH1–Regulated IDH3β Coordinates with the Cell Cycle to Promote Cell Proliferation

Qingnan Wu,Weimin Zhang,Liyan Xue,Yan Wang,Ming Fu,Liying Ma,Yongmei Song,Qi-Min Zhan

DOI: https://doi.org/10.1158/0008-5472.22421001

2023-01-01

Abstract:Supplementary Table S2 Metabolic gene with CNV larger than 20%.

What problem does this paper attempt to address?

Table S1 from APC/C-CDH1–Regulated IDH3β Coordinates with the Cell Cycle to Promote Cell Proliferation

Qingnan Wu,Weimin Zhang,Liyan Xue,Yan Wang,Ming Fu,Liying Ma,Yongmei Song,Qi-Min Zhan

DOI: https://doi.org/10.1158/0008-5472.22421004

2023-01-01

Abstract:Supplementary Table S1 Metabolic gene with KEN box and D box.
Table S3 from APC/C-CDH1–Regulated IDH3β Coordinates with the Cell Cycle to Promote Cell Proliferation

Qingnan Wu,Weimin Zhang,Liyan Xue,Yan Wang,Ming Fu,Liying Ma,Yongmei Song,Qi-Min Zhan

DOI: https://doi.org/10.1158/0008-5472.22420998

2023-01-01

Abstract:Supplementary Table S3 The clinicopathological characteristics of 340 ESCC samples.
Supplementary Figures and Figure Legends from APC/C-CDH1–Regulated IDH3β Coordinates with the Cell Cycle to Promote Cell Proliferation

Qingnan Wu,Weimin Zhang,Liyan Xue,Yan Wang,Ming Fu,Liying Ma,Yongmei Song,Qi-Min Zhan

DOI: https://doi.org/10.1158/0008-5472.22421010

2023-01-01

Abstract:Fig S1. The changing trend of Î±-KG, fumarate and malate were significantly correlated with S phase.Fig S2. IDH3Î² accumulated in late G1 phase and CDC20 was not the regulator of IDH3Î². Fig S3. The interaction of IDH3Î² and CDH1 was strong in G1 and weak in G2/M. Fig .S4 IDH3Î² regulated the G1/S transition and cell proliferation. Fig .S5 Xenograft tumor formation of stable IDH3Î² overexpressed KYSE410 cells and control cells.Fig .S6 IDH3Î±, IDH3Î² and IDH3Î³ contribute to oxidative metabolism in TCA cycle.Fig .S7 IDH3Î²-dependent Î±-KG generation accounts for improving cell proliferation. Fig .S8 IDH3Î² enhances cytoplasmic PFKFB3 level in IDH3Î² overexpressed cell.
Data from APC/C-CDH1–Regulated IDH3β Coordinates with the Cell Cycle to Promote Cell Proliferation

Qingnan Wu,Weimin Zhang,Liyan Xue,Yan Wang,Ming Fu,Liying Ma,Yongmei Song,Qi-Min Zhan

DOI: https://doi.org/10.1158/0008-5472.can-18-2341

IF: 11.2

2019-01-01

Cancer Research

Abstract:AbstractMetabolic activities are often accompanied by cell-cycle progression, yet known connections between these two processes remain limited. Here, we identified the isocitrate dehydrogenase 3β (IDH3β) as a novel substrate of anaphase-promoting complex/cyclosome (APC/C)-CDH1 and an important regulator of the cell cycle. In esophageal squamous cell carcinoma (ESCC), IDH3β was posttranslationally upregulated in late G1 phase, and overexpression of IDH3β accelerated G1–S transition, contributing to the promotion of cell proliferation in vitro and in vivo. α-Ketoglutarate (α-KG), a crucial metabolite in tricarboxylic acid (TCA) cycle, was dependent on IDH3β level and partially accounted for IDH3β-mediated cell growth. IDH3β expression increased PFKFB3 protein levels and enhanced glucose uptake, and high expression of IDH3β correlated with poor survival in patients with ESCC, suggesting a potential application of IDH3β in prognosis. Overall, our results highlight a new molecular connection between cell-cycle regulation and the TCA cycle in ESCC.Significance:These findings show that IDH3β is an APC/C-CDH1 substrate and is expressed in a cell-cycle–dependent manner, highlighting novel molecular cross-talk between the TCA cycle and cell cycle in cancer cells.
Supplementary Materials and Methods from APC/C-CDH1–Regulated IDH3β Coordinates with the Cell Cycle to Promote Cell Proliferation

Qingnan Wu,Weimin Zhang,Liyan Xue,Yan Wang,Ming Fu,Liying Ma,Yongmei Song,Qi-Min Zhan

DOI: https://doi.org/10.1158/0008-5472.22421007

2023-01-01

Abstract:Quantitative real-time PCR analysisï¼ŒProliferation assay and colony formation assayï¼ŒCell cycle analysisï¼ŒMetabolite measurement.
Additional File 9 of CircCDKN2B-AS1 Interacts with IMP3 to Stabilize Hexokinase 2 Mrna and Facilitate Cervical Squamous Cell Carcinoma Aerobic Glycolysis Progression

Yanan Zhang,Liang Zhao,Shizhou Yang,Yixuan Cen,Tingjia Zhu,Lingfang Wang,Lili Xia,Yuwan Liu,Jian Zou,Junfen Xu,Yang Li,Xiaodong Cheng,Weiguo Lü,Xinyu Wang,Xian-Jin Xie

DOI: https://doi.org/10.6084/m9.figshare.13466847

2020-01-01

Abstract:Additional file 9: Table S5. All proteins predicted by RBPmap.
Supplemental Table S1 from PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease

Zejuan Li,Ping Chen,Rui Su,Chao Hu,Yuanyuan Li,Abdel G. Elkahloun,Zhixiang Zuo,Sandeep Gurbuxani,Stephen Arnovitz,Hengyou Weng,Yungui Wang,Shenglai Li,Hao Huang,Mary Beth Neilly,Gang Greg Wang,Xi Jiang,Paul P. Liu,Jie Jin,Jianjun Chen

DOI: https://doi.org/10.1158/0008-5472.22408335.v1

2023-01-01

Abstract:List of the 1,190 genes that are expressed at a significantly higher level in Group 1 than in both Groups 2 and 3.
Supplementary Figure 1 from Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15Q24-25.1

Yan Liu,Pengyuan Liu,Weidong Wen,Michael A. James,Yian Wang,Joan E. Bailey-Wilson,Christopher I. Amos,Susan M. Pinney,Ping Yang,Mariza de Andrade,Gloria M. Petersen,Jonathan S. Wiest,Pamela R. Fain,Ann G. Schwartz,Adi Gazdar,Colette Gaba,Henry Rothschild,Diptasri Mandal,Elena Kupert,Juwon Lee,Daniela Seminara,John Minna,Marshall W. Anderson,Ming You

DOI: https://doi.org/10.1158/0008-5472.22382063

2023-01-01

Abstract:Supplementary Figure 1 from Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15q24-25.1
P89.07 A Large-Scale Survey of IDH1/2 Mutation in Chinese Patients with NSCLC

M. Jin,J. Zhang,H. Zhu,S. Chen,Z. Liu,J. Li,S. Hao,J. Luo,D. Wang,T. Ma,L. Dong,L. Teng,J. Liu,X. Li

DOI: https://doi.org/10.1016/j.jtho.2021.01.1272

IF: 20.121

2021-01-01

Journal of Thoracic Oncology

Abstract:Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes, which catalyzes isocitrate to α-ketoglutarate (αKG). Mutations of IDH family were identified in multiple tumor types, including sarcomas, hematologic malignancies, brain cancer and bile duct carcinoma. And the IDH mutation proteins confer neomorphic activity, resulting in the conversion of αKG to D-2-hydroxyglutarate (2-HG) and epigenetic dysregulation via accumulation of 2-HG. Increasing preclinical studies and clinical trials indicating that IDH mutation inhibitors could reverse epigenetic dysregulation and induce cellular differentiation by decrease intracellular 2-HG accumulation.
Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395236.v1

2023-01-01

Abstract:Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Supplementary Tables S1-S5 from Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer

Fu-Gui Ye,Chuan-Gui Song,Zhi-Gang Cao,Chen Xia,Dan-Na Chen,Li Chen,Shan Li,Feng Qiao,Hong Ling,Ling Yao,Xin Hu,Zhi-Ming Shao

DOI: https://doi.org/10.1158/0008-5472.22406621

2023-01-01

Abstract:Supplementary Tables S1-S5: Final concentrations of gemcitabine in the culture medium corresponding to each cycle (S1); Nucletide sequences of PCR primers used for amplification of ALDH1A3, CDA, DST, FMO3, MAOA, PTHLH, XDH, UGT1A1, hENT1, NT5C, DCK, DCTD, CMPK1, NME1 (S2); Selected Genes Related to Drug Metabolism/Resistance according to the GO analysis (S3); Clinicopathological variables and CDA expression in the studied cases (S4); Univariate and multivariate analysis of DFS (S5).
Supplementary Table 7 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395233

2023-01-01

Abstract:Supplementary Table 7 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Supplementary Table S4 from A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study

Wenju Chang,Zhou Zhang,Baoqing Jia,Kefeng Ding,Zhizhong Pan,Guoqiang Su,Wei Zhang,Tianyu Liu,Yunshi Zhong,Guodong He,Li Ren,Ye Wei,Dongdong Li,Xiaolong Cui,Jun Yang,Yixiang Shi,Marc Bissonnette,Chuan He,Wei Zhang,Jia Fan,Jianmin Xu

DOI: https://doi.org/10.1158/1078-0432.26422958.v1

2024-01-01

Abstract:Differetially modified gene bodies between CRC/AA and controls.
Supplementary Figure S10 from A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study

Wenju Chang,Zhou Zhang,Baoqing Jia,Kefeng Ding,Zhizhong Pan,Guoqiang Su,Wei Zhang,Tianyu Liu,Yunshi Zhong,Guodong He,Li Ren,Ye Wei,Dongdong Li,Xiaolong Cui,Jun Yang,Yixiang Shi,Marc Bissonnette,Chuan He,Wei Zhang,Jia Fan,Jianmin Xu

DOI: https://doi.org/10.1158/1078-0432.26423000

2024-01-01

Abstract:The interaction and/or co-modification modules identified from the candidate marker genes.
Supplementary Table from Proteomic Mapping and Targeting of Mitotic Pericentriolar Material in Tumors Bearing Centrosome Amplification

Bingteng Xie,Yang Pu,Fan Yang,Wei Chen,Wei Yue,Jihong Ma,Na Zhang,Yuening Jiang,Jiegen Wu,Yihan Lin,Xin Liang,Chu Wang,Peng Zou,Mo Li

DOI: https://doi.org/10.1158/0008-5472.22432052

2023-01-01

Abstract:Supplementary Table from Proteomic Mapping and Targeting of Mitotic Pericentriolar Material in Tumors Bearing Centrosome Amplification
Ectopic expression of the transcription factor ONECUT3 drives a complex karyotype in myelodysplastic syndromes.

Yingwan Luo,Xiaomin Feng,Wei Lang,Weihong Xu,Wei Wang,Chen Mei,Li Ye,Shuanghong Zhu,Lu Wang,Xinping Zhou,Huimin Zeng,Liya Ma,Yanling Ren,Jie Jin,Rongzhen Xu,Gang Huang,Hongyan Tong

DOI: https://doi.org/10.1172/JCI172468

2024-01-01

Abstract:Chromosomal instability is a prominent biological feature of myelodysplastic syndromes (MDS), with over 50% of patients with MDS harboring chromosomal abnormalities or a complex karyotype (CK). Despite this observation, the mechanisms underlying mitotic and chromosomal defects in MDS remain elusive. In this study, we identified ectopic expression of the transcription factor ONECUT3, which is associated with CKs and poorer survival outcomes in MDS. ONECUT3-overexpressing cell models exhibited enrichment of several notable pathways, including signatures of sister chromosome exchange separation and mitotic nuclear division with the upregulation of INCENP and CDCA8 genes. Notably, dysregulation of chromosome passenger complex (CPC) accumulation, besides the cell equator and midbody, during mitotic phases consequently caused cytokinesis failure and defective chromosome segregation. Mechanistically, the homeobox (HOX) domain of ONECUT3, serving as the DNA binding domain, occupied the unique genomic regions of INCENP and CDCA8 and transcriptionally activated these 2 genes. We identified a lead compound, C5484617, that functionally targeted the HOX domain of ONECUT3, inhibiting its transcriptional activity on downstream genes, and synergistically resensitized MDS cells to hypomethylating agents. This study revealed that ONECUT3 promoted chromosomal instability by transcriptional activation of INCENP and CDCA8, suggesting potential prognostic and therapeutic roles for targeting high-risk MDS patients with a CK.
Table S2 from ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression

Qiaodan Deng

DOI: https://doi.org/10.1158/0008-5472.22429815

2023-01-01

Abstract:Primer sequences for plasmid construction
Supplementary Table 1-4 from Long Noncoding RNA neat1, Regulated by the EGFR Pathway, Contributes to Glioblastoma Progression Through the WNT/β-Catenin Pathway by Scaffolding EZH2

Qun Chen,Jinquan Cai,Qixue Wang,Yunfei Wang,Mingyang Li,Jingxuan Yang,Junhu Zhou,Chunsheng Kang,Min Li,Chuanlu Jiang

DOI: https://doi.org/10.1158/1078-0432.22464864.v1

2023-01-01

Abstract:Supplementary Table 1. The characteristics of CGGA database. Supplementary Table 2. The characteristics of Rembrandt database. Supplementary Table 3. The characteristics of TCGA database. Supplementary Table 4. The characteristics of GSE16011 database.
PATH-23. GENOMIC LANDSCAPE OF IDH-MUTANT PRIMARY GLIOBLASTOMAS SHOWS DISTINCT CLINICAL AND MOLECULAR FEATURES AND THAT CDKN2A SHOULD BE SUPPLEMENTED WITH MGMTp AND G-CIMP FOR PRECISE PROGNOSTICATION

Queenie Hoi-Wing Wong,Gabriel Chun-Hei Wong,Aden Ka-Yin Chan,Wai Sang Poon,Danny Tat-Ming Chan,Hong Chen,Zhen-yu Zhang,Houtan Noushmehr,Chris Jones,Yura Grabovska,Alan Mackay,Chit Chow,Johnny Sheung Him Kwan,Nellie Yuk-Fei Chung,Queenie Junqi Huang,Manix Fung-Man Poon,Zhi-feng Shi,Kay Ka-Wai Li,Ho-Keung Ng

DOI: https://doi.org/10.1093/neuonc/noaa215.704

2020-01-01

Neuro-Oncology

Abstract:There have only been rare studies of IDH-mutant primary glioblastomas (IDH-mutant astrocytoma IV); there were one or two studies on secondary glioblastomas. In a cohort of 70 cases, we conducted clinical analysis, methylation profiling, RNA sequencing, targeted sequencing, and TERTp seqeuncing on available FFPE tissues. Median follow-up was 58.2 months (n= 60). IDH-mutant primary glioblastomas had longer median OS (30.4 months) and median PFS (25.9 months) than IDH-mutant secondary glioblastomas as in the literature or established databases. MGMTp methylated cases had better OS (p= 0.001) and it was an independent prognosticator. We previously showed G-CIMP to be an independent prognostic marker for IDH-mutant glioblastomas (NOA 2019). Although CDKN2A deletion was an independent prognostic marker for poorer OS (p= 0.036) and PFS (p= 0.005), MGMTp methylation had a trend of superseding CDKN2A deletion (p= 0.055) for prognostication and G-CIMP subgroups could similarly partially supersede CDKN2A deletion (p= 0.582). Hence, CDKN2A deletion should be supplemented with these two biomarkers for finer prognostication. Targeted sequencing (n= 55) showed that there were more ATRX (35/55, 64%), TP53 (31/55, 56%), KMT2D (18/55, 33%), POLE (11/55, 20%) and MSH6 (7/55, 13%) mutations, but fewer TERTp (3/69, 4%) and PTEN (1/55, 2%) mutations than IDH-wildtype glioblastomas as from literature and databases. CNVs revealed by methylomes (n= 53) and mutations (n= 55) showed that there were more PDGFRA (amplification: 9/53, 17%, mutation: 10/55, 18%) alterations, but fewer MET (amplification: 3/53, 6%, mutation: 4/55, 7%) alterations and hypermutated (6/55, 11%) cases than IDH-mutant secondary glioblastomas from literature. GISTIC analysis revealed amplifications of CCND2, CDK4, MYC, and PDGFRA, deletions of CDKN2A, RB1, and chromosome 10q to be significant CNVs (q< 0.05). There were few EGFR amplifications (2/53, 4%), which was different from regular glioblastomas. RNA sequencing (n= 42) showed few fusions (4/42, 10%), which was different from IDH-mutant secondary glioblastomas.
Supplementary Table 5 from The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease

Yi-Ping Fu,Indu Kohaar,Lee E. Moore,Petra Lenz,Jonine D. Figueroa,Wei Tang,Patricia Porter-Gill,Nilanjan Chatterjee,Alexandra Scott-Johnson,Montserrat Garcia-Closas,Brian Muchmore,Dalsu Baris,Ashley Paquin,Kris Ylaya,Molly Schwenn,Andrea B. Apolo,Margaret R. Karagas,McAnthony Tarway,Alison Johnson,Adam Mumy,Alan Schned,Liliana Guedez,Michael A. Jones,Masatoshi Kida,GM Monawar Hosain,Nuria Malats,Manolis Kogevinas,Adonina Tardon,Consol Serra,Alfredo Carrato,Reina Garcia-Closas,Josep Lloreta,Xifeng Wu,Mark Purdue,Gerald L. Andriole,Robert L. Grubb,Amanda Black,Maria T. Landi,Neil E. Caporaso,Paolo Vineis,Afshan Siddiq,H. Bas Bueno-de-Mesquita,Dimitrios Trichopoulos,Börje Ljungberg,Gianluca Severi,Elisabete Weiderpass,Vittorio Krogh,Miren Dorronsoro,Ruth C. Travis,Anne Tjønneland,Paul Brennan,Jenny Chang-Claude,Elio Riboli,Jennifer Prescott,Constance Chen,Immaculata De Vivo,Edward Govannucci,David Hunter,Peter Kraft,Sara Lindstrom,Susan M. Gapstur,Eric J. Jacobs,W. Ryan Diver,Demetrius Albanes,Stephanie J. Weinstein,Jarmo Virtamo,Charles Kooperberg,Chancellor Hohensee,Rebecca J. Rodabough,Victoria K. Cortessis,David V. Conti,Manuela Gago-Dominguez,Mariana C. Stern,Malcolm C. Pike,David Van Den Berg,Jian-Min Yuan,Christopher A. Haiman,Olivier Cussenot,Geraldine Cancel-Tassin,Morgan Roupret,Eva Comperat,Stefano Porru,Angela Carta,Sofia Pavanello,Cecilia Arici,Giuseppe Mastrangelo,H. Barton Grossman,Zhaoming Wang,Xiang Deng,Charles C. Chung,Amy Hutchinson,Laurie Burdette,William Wheeler,Joseph Fraumeni,Stephen J. Chanock,Stephen M. Hewitt,Debra T. Silverman,Nathaniel Rothman,Ludmila Prokunina-Olsson

DOI: https://doi.org/10.1158/0008-5472.22403564

2023-01-01

Abstract:Association between CCNE1 variants and bladder cancer

Table S2 from APC/C-CDH1–Regulated IDH3β Coordinates with the Cell Cycle to Promote Cell Proliferation

Table S1 from APC/C-CDH1–Regulated IDH3β Coordinates with the Cell Cycle to Promote Cell Proliferation

Table S3 from APC/C-CDH1–Regulated IDH3β Coordinates with the Cell Cycle to Promote Cell Proliferation

Supplementary Figures and Figure Legends from APC/C-CDH1–Regulated IDH3β Coordinates with the Cell Cycle to Promote Cell Proliferation

Data from APC/C-CDH1–Regulated IDH3β Coordinates with the Cell Cycle to Promote Cell Proliferation

Supplementary Materials and Methods from APC/C-CDH1–Regulated IDH3β Coordinates with the Cell Cycle to Promote Cell Proliferation

Additional File 9 of CircCDKN2B-AS1 Interacts with IMP3 to Stabilize Hexokinase 2 Mrna and Facilitate Cervical Squamous Cell Carcinoma Aerobic Glycolysis Progression

Supplemental Table S1 from PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease

Supplementary Figure 1 from Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15Q24-25.1

P89.07 A Large-Scale Survey of IDH1/2 Mutation in Chinese Patients with NSCLC

Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Supplementary Tables S1-S5 from Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer

Supplementary Table 7 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Supplementary Table S4 from A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study

Supplementary Figure S10 from A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study

Supplementary Table from Proteomic Mapping and Targeting of Mitotic Pericentriolar Material in Tumors Bearing Centrosome Amplification

Ectopic expression of the transcription factor ONECUT3 drives a complex karyotype in myelodysplastic syndromes.

Table S2 from ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression

Supplementary Table 1-4 from Long Noncoding RNA &lt;i&gt;neat1&lt;/i&gt;, Regulated by the EGFR Pathway, Contributes to Glioblastoma Progression Through the WNT/&lt;b&gt;β&lt;/b&gt;-Catenin Pathway by Scaffolding EZH2

PATH-23. GENOMIC LANDSCAPE OF IDH-MUTANT PRIMARY GLIOBLASTOMAS SHOWS DISTINCT CLINICAL AND MOLECULAR FEATURES AND THAT CDKN2A SHOULD BE SUPPLEMENTED WITH MGMTp AND G-CIMP FOR PRECISE PROGNOSTICATION

Supplementary Table 5 from The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease

Supplementary Table 1-4 from Long Noncoding RNA <i>neat1</i>, Regulated by the EGFR Pathway, Contributes to Glioblastoma Progression Through the WNT/<b>β</b>-Catenin Pathway by Scaffolding EZH2